CENP-I (Centromere Protein I) is a crucial component of the centromere, a specialized region on chromosomes essential for proper chromosome segregation during cell division. The activation or modulation of CENP-I is of interest in cell biology research to understand its role in maintaining genome stability and faithful chromosome segregation. Various chemicals and biological processes can indirectly influence CENP-I function by affecting centromere dynamics and integrity.
One group of compounds that can indirectly activate or modulate CENP-I are those involved in cell cycle regulation. For instance, CDK (Cyclin-Dependent Kinase) inhibitors like Roscovitine can impact CENP-I by altering the progression of the cell cycle. By inhibiting CDKs, Roscovitine can influence the timing of centromere events, ensuring proper chromosome alignment and segregation. Similarly, Aurora kinase inhibitors such as VX-680 can indirectly activate CENP-I by promoting centromere stability during cell division. These compounds interfere with key regulators of the cell cycle and centromere function, affecting CENP-I as part of this intricate process. Additionally, epigenetic modifiers like SAHA (Suberanilohydroxamic Acid, also known as Vorinostat) can indirectly influence CENP-I. SAHA is an HDAC (Histone Deacetylase) inhibitor that affects chromatin structure and gene expression. Given that centromere function is intricately linked to chromatin dynamics, SAHA can modulate the transcription of genes related to centromere stability and indirectly impact CENP-I function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $61.00 $85.00 | 4 | |
Tozasertib (VX-680) inhibits Aurora kinases, indirectly activating CENP-I by promoting centromere stability during cell division. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine inhibits CDKs, indirectly influencing CENP-I by modulating cell cycle progression and centromere dynamics. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
SAHA is an HDAC inhibitor that indirectly affects CENP-I by altering chromatin structure and gene expression related to centromere stability. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 inhibits the proteasome, indirectly influencing CENP-I by maintaining its protein levels and stability. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Taxol disrupts microtubules, indirectly affecting CENP-I by influencing centromere-microtubule interactions during mitosis. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Etoposide inhibits topoisomerases, indirectly impacting CENP-I through DNA structure-related processes affecting centromere stability. | ||||||
GSK 923295 | 1088965-37-0 | sc-490136 | 5 mg | $290.00 | ||
GSK-923295 indirectly influences CENP-I by affecting processes related to mitotic progression and centromere function. | ||||||
BI 2536 | 755038-02-9 | sc-364431 sc-364431A | 5 mg 50 mg | $148.00 $515.00 | 8 | |
BI 2536 inhibits Plk1, indirectly impacting CENP-I function related to centromere stability during cell division. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
5-Aza-2′-Deoxycytidine (Decitabine) indirectly influences CENP-I through epigenetic modifications affecting centromere structure and stability. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Doxorubicin induces DNA damage responses, indirectly influencing CENP-I-related centromere stability through cellular stress responses. | ||||||